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Characterization of genetic diversity among locally
prevalent parasite strains and the ensuing strain-specific
immunity will be particularly important in a specific
geographical setting for development of vaccine con-
structs and for planning future vaccination strategies.
The present study characterized the prevailing genetic
diversity of three major asexual stage putative vaccine
antigens of Plasmodium vivax, 42 kDa fragment of the
Merozoite Surface Protein -1 (MSP-142), Apical Mem-
brane Antigen-1 domain II (AMA-1 DII) and the Duffy
Binding Protein region II (PvDBPII), in patients infected
with P. vivax malaria from two endemic areas, Anurad-
hapura and Kataragama, in Sri Lanka, where unstable
malaria prevails with low transmission, and from a
malaria non-endemic area, Colombo, where the patients
contracted the infections while visiting areas endemic to
vivax malaria. Based on nucleotide sequences, extensive
allelic polymorphism was evident in the N-terminal
region of MSP-142(Pvmsp-133), Pvama- 1dII and
PvdbpII, due to recombination, mutations, natural selec-
tion and genetic differentiation. Nucleotide sequences of
Pvmsp-142(N=95), Pvama-1dII (64) and PvdbpII (100),
generated 27, 21 and 33 amino acid (a.a) haplotypes,
respectively. Clinical isolates with amino acid haplotypes
available for all three antigens (N=24) revealed uniquely
different haplotype combinations in each isolate.
Conversely, PvMSP-119,d o m a i nI Il o o po fP v A M A - 1
and the six a.a. in the critical binding domain of
PvDBPII responsible for direct binding with the Duffy
antigen on human RBC, showed 100% conservation of
the amino acid sequences.
In order to evaluate whether sequence differences
among each antigen was indicative of strain-specific
immunity, amino acid sequences of PvMSP-142, PvAMA-
1DII and PvDBPII were aligned with the homologous total
(IgM + IgG) antibody responses assayed by ELISA against
the recombinant protein of each antigen, and the seven
(P01-P07) PvAMA-1DII peptides. Though Anti-PvMSP-
119 and anti-P04 antibody prevalence precludes strain-
specific immune responses against the highly conserved
PvMSP-119 and the P04 peptide on domain II loop of
PvAMA-1, a protective immune response was clearly eli-
cited to these two regions by the marked isotype switch
from IgM to IgG with increasing exposure in areas of
endemicity. Further, the presence of strain transcending
(cross reactive) PvDBPII specific functionally active bind-
ing inhibitory antibodies were demonstrated among locally
exposed P. vivax patients. Thus this study may support the
inclusion of PvMSP-119, P04 region of PvAMA-1 domain
II and region II of PvDBP as veritable vaccine components
for a multi component “cocktail” asexual stage vaccine
against P. vivax malaria in Sri Lanka.
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